{"id":860635,"date":"2025-06-16T05:50:31","date_gmt":"2025-06-16T09:50:31","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/urogen-pharma-ltd-class-action-the-gross-law-firm-reminds-urogen-pharma-ltd-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-july-28-2025-urgn\/"},"modified":"2025-06-16T05:50:31","modified_gmt":"2025-06-16T09:50:31","slug":"urogen-pharma-ltd-class-action-the-gross-law-firm-reminds-urogen-pharma-ltd-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-july-28-2025-urgn","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/urogen-pharma-ltd-class-action-the-gross-law-firm-reminds-urogen-pharma-ltd-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-july-28-2025-urgn\/","title":{"rendered":"UroGen Pharma Ltd. Class Action: The Gross Law Firm Reminds UroGen Pharma Ltd. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 28, 2025 &#8211; URGN"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"legendSpanClass\"><br \/>\n          <span class=\"xn-location\">NEW YORK<\/span><br \/>\n        <\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">June 16, 2025<\/span><\/span> \/PRNewswire\/ &#8212; The Gross Law Firm issues the following notice to shareholders of\u00a0<b>UroGen Pharma Ltd. (NASDAQ: URGN).<\/b><\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/2280333\/The_Gross_Law_Firm_Logo.html\" target=\"_blank\" rel=\"nofollow\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/2280333\/The_Gross_Law_Firm_Logo.jpg\" title=\"The Gross Law Firm (PRNewsfoto\/The Gross Law Firm)\" alt=\"The Gross Law Firm (PRNewsfoto\/The Gross Law Firm)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>Shareholders who purchased shares of URGN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.<\/p>\n<p class=\"prntac\">CONTACT US HERE:<\/p>\n<p class=\"prntac\">\n        <a href=\"https:\/\/securitiesclasslaw.com\/securities\/urogen-pharma-ltd-loss-submission-form\/?id=152954&amp;from=4\" rel=\"nofollow\">https:\/\/securitiesclasslaw.com\/securities\/urogen-pharma-ltd-loss-submission-form\/?id=152954&amp;from=4<\/a>\n      <\/p>\n<p>\n        <b>CLASS PERIOD: <\/b><br \/>\n        <span class=\"xn-chron\">July 27, 2023<\/span> to <span class=\"xn-chron\">May 15, 2025<\/span><\/p>\n<p>\n        <b>ALLEGATIONS: <\/b>The complaint <span>alleges<\/span> that during the class period, Defendants issued materially false and\/or misleading statements and\/or failed to disclose that: (1) the ENVISION clinical study was not designed to demonstrate substantial evidence of effectiveness of the Company&#8217;s lead pipeline product, UGN-102, because it lacked a concurrent control arm; (2) as a result, the Company would have difficulty demonstrating that the duration of response endpoint was attributable to UGN-102; (3) UroGen failed to heed the FDA&#8217;s warnings about the study design used to support a drug application for UGN-102; (4) as a result of the foregoing, there was a substantial risk that the NDA for UGN-102 would not be approved; and (5) as a result of the foregoing, defendants&#8217; positive statements about the Company&#8217;s business, operations, and prospects were materially misleading and\/or lacked a reasonable basis.<\/p>\n<p>\n        <b>DEADLINE: <span class=\"xn-chron\">July 28, 2025<\/span><\/b> Shareholders should not delay in registering for this class action. Register your information here: <a href=\"https:\/\/securitiesclasslaw.com\/securities\/urogen-pharma-ltd-loss-submission-form\/?id=152954&amp;from=4\" rel=\"nofollow\">https:\/\/securitiesclasslaw.com\/securities\/urogen-pharma-ltd-loss-submission-form\/?id=152954&amp;from=4<\/a><\/p>\n<p>\n        <b>NEXT STEPS FOR SHAREHOLDERS: <\/b>Once you register as a shareholder who purchased shares of URGN during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is <span class=\"xn-chron\">July 28, 2025<\/span>. There is no cost or obligation to you to participate in this case.<\/p>\n<p>\n        <b>WHY GROSS LAW FIRM? <\/b>The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, <span>fraud<\/span>, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and\/or misleading statements or the omission of material information by a company lead to artificial inflation of the company&#8217;s stock. Attorney advertising. Prior results do not guarantee similar outcomes.<\/p>\n<p>\n        <b>CONTACT:<\/b><br \/>\n        <br \/>The Gross Law Firm<br \/>15 West 38th Street, 12th floor<br \/><span class=\"xn-location\">New York, NY<\/span>, 10018<br \/>Email: <a href=\"mailto:dg@securitiesclasslaw.com\" rel=\"nofollow\">dg@securitiesclasslaw.com<\/a><br \/>Phone: (646) 453-8903<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY10424&amp;sd=2025-06-16\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/urogen-pharma-ltd-class-action-the-gross-law-firm-reminds-urogen-pharma-ltd-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-july-28-2025--urgn-302481568.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/urogen-pharma-ltd-class-action-the-gross-law-firm-reminds-urogen-pharma-ltd-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-july-28-2025&#8211;urgn-302481568.html<\/a><\/p>\n<p>SOURCE  The Gross Law Firm<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=NY10424&amp;Transmission_Id=202506160545PR_NEWS_USPR_____NY10424&amp;DateId=20250616\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire NEW YORK , June 16, 2025 \/PRNewswire\/ &#8212; The Gross Law Firm issues the following notice to shareholders of\u00a0UroGen Pharma Ltd. (NASDAQ: URGN). Shareholders who purchased shares of URGN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https:\/\/securitiesclasslaw.com\/securities\/urogen-pharma-ltd-loss-submission-form\/?id=152954&amp;from=4 CLASS PERIOD: July 27, 2023 to May 15, 2025 ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and\/or misleading statements and\/or failed to disclose that: (1) the ENVISION clinical study was not designed to demonstrate substantial evidence of effectiveness of the Company&#8217;s lead pipeline product, UGN-102, because it lacked a concurrent control &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/urogen-pharma-ltd-class-action-the-gross-law-firm-reminds-urogen-pharma-ltd-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-july-28-2025-urgn\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;UroGen Pharma Ltd. Class Action: The Gross Law Firm Reminds UroGen Pharma Ltd. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 28, 2025 &#8211; URGN&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-860635","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>UroGen Pharma Ltd. Class Action: The Gross Law Firm Reminds UroGen Pharma Ltd. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 28, 2025 - URGN - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/urogen-pharma-ltd-class-action-the-gross-law-firm-reminds-urogen-pharma-ltd-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-july-28-2025-urgn\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"UroGen Pharma Ltd. Class Action: The Gross Law Firm Reminds UroGen Pharma Ltd. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 28, 2025 - URGN - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire NEW YORK , June 16, 2025 \/PRNewswire\/ &#8212; The Gross Law Firm issues the following notice to shareholders of\u00a0UroGen Pharma Ltd. (NASDAQ: URGN). Shareholders who purchased shares of URGN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https:\/\/securitiesclasslaw.com\/securities\/urogen-pharma-ltd-loss-submission-form\/?id=152954&amp;from=4 CLASS PERIOD: July 27, 2023 to May 15, 2025 ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and\/or misleading statements and\/or failed to disclose that: (1) the ENVISION clinical study was not designed to demonstrate substantial evidence of effectiveness of the Company&#8217;s lead pipeline product, UGN-102, because it lacked a concurrent control &hellip; Continue reading &quot;UroGen Pharma Ltd. Class Action: The Gross Law Firm Reminds UroGen Pharma Ltd. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 28, 2025 &#8211; URGN&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/urogen-pharma-ltd-class-action-the-gross-law-firm-reminds-urogen-pharma-ltd-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-july-28-2025-urgn\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-16T09:50:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/2280333\/The_Gross_Law_Firm_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/urogen-pharma-ltd-class-action-the-gross-law-firm-reminds-urogen-pharma-ltd-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-july-28-2025-urgn\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/urogen-pharma-ltd-class-action-the-gross-law-firm-reminds-urogen-pharma-ltd-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-july-28-2025-urgn\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"UroGen Pharma Ltd. Class Action: The Gross Law Firm Reminds UroGen Pharma Ltd. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 28, 2025 &#8211; URGN\",\"datePublished\":\"2025-06-16T09:50:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/urogen-pharma-ltd-class-action-the-gross-law-firm-reminds-urogen-pharma-ltd-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-july-28-2025-urgn\\\/\"},\"wordCount\":468,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/urogen-pharma-ltd-class-action-the-gross-law-firm-reminds-urogen-pharma-ltd-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-july-28-2025-urgn\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2280333\\\/The_Gross_Law_Firm_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/urogen-pharma-ltd-class-action-the-gross-law-firm-reminds-urogen-pharma-ltd-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-july-28-2025-urgn\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/urogen-pharma-ltd-class-action-the-gross-law-firm-reminds-urogen-pharma-ltd-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-july-28-2025-urgn\\\/\",\"name\":\"UroGen Pharma Ltd. Class Action: The Gross Law Firm Reminds UroGen Pharma Ltd. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 28, 2025 - URGN - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/urogen-pharma-ltd-class-action-the-gross-law-firm-reminds-urogen-pharma-ltd-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-july-28-2025-urgn\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/urogen-pharma-ltd-class-action-the-gross-law-firm-reminds-urogen-pharma-ltd-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-july-28-2025-urgn\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2280333\\\/The_Gross_Law_Firm_Logo.jpg\",\"datePublished\":\"2025-06-16T09:50:31+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/urogen-pharma-ltd-class-action-the-gross-law-firm-reminds-urogen-pharma-ltd-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-july-28-2025-urgn\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/urogen-pharma-ltd-class-action-the-gross-law-firm-reminds-urogen-pharma-ltd-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-july-28-2025-urgn\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/urogen-pharma-ltd-class-action-the-gross-law-firm-reminds-urogen-pharma-ltd-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-july-28-2025-urgn\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2280333\\\/The_Gross_Law_Firm_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2280333\\\/The_Gross_Law_Firm_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/urogen-pharma-ltd-class-action-the-gross-law-firm-reminds-urogen-pharma-ltd-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-july-28-2025-urgn\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"UroGen Pharma Ltd. Class Action: The Gross Law Firm Reminds UroGen Pharma Ltd. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 28, 2025 &#8211; URGN\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"UroGen Pharma Ltd. Class Action: The Gross Law Firm Reminds UroGen Pharma Ltd. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 28, 2025 - URGN - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/urogen-pharma-ltd-class-action-the-gross-law-firm-reminds-urogen-pharma-ltd-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-july-28-2025-urgn\/","og_locale":"en_US","og_type":"article","og_title":"UroGen Pharma Ltd. Class Action: The Gross Law Firm Reminds UroGen Pharma Ltd. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 28, 2025 - URGN - Market Newsdesk","og_description":"PR Newswire NEW YORK , June 16, 2025 \/PRNewswire\/ &#8212; The Gross Law Firm issues the following notice to shareholders of\u00a0UroGen Pharma Ltd. (NASDAQ: URGN). Shareholders who purchased shares of URGN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https:\/\/securitiesclasslaw.com\/securities\/urogen-pharma-ltd-loss-submission-form\/?id=152954&amp;from=4 CLASS PERIOD: July 27, 2023 to May 15, 2025 ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and\/or misleading statements and\/or failed to disclose that: (1) the ENVISION clinical study was not designed to demonstrate substantial evidence of effectiveness of the Company&#8217;s lead pipeline product, UGN-102, because it lacked a concurrent control &hellip; Continue reading \"UroGen Pharma Ltd. Class Action: The Gross Law Firm Reminds UroGen Pharma Ltd. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 28, 2025 &#8211; URGN\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/urogen-pharma-ltd-class-action-the-gross-law-firm-reminds-urogen-pharma-ltd-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-july-28-2025-urgn\/","og_site_name":"Market Newsdesk","article_published_time":"2025-06-16T09:50:31+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/2280333\/The_Gross_Law_Firm_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/urogen-pharma-ltd-class-action-the-gross-law-firm-reminds-urogen-pharma-ltd-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-july-28-2025-urgn\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/urogen-pharma-ltd-class-action-the-gross-law-firm-reminds-urogen-pharma-ltd-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-july-28-2025-urgn\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"UroGen Pharma Ltd. Class Action: The Gross Law Firm Reminds UroGen Pharma Ltd. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 28, 2025 &#8211; URGN","datePublished":"2025-06-16T09:50:31+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/urogen-pharma-ltd-class-action-the-gross-law-firm-reminds-urogen-pharma-ltd-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-july-28-2025-urgn\/"},"wordCount":468,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/urogen-pharma-ltd-class-action-the-gross-law-firm-reminds-urogen-pharma-ltd-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-july-28-2025-urgn\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2280333\/The_Gross_Law_Firm_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/urogen-pharma-ltd-class-action-the-gross-law-firm-reminds-urogen-pharma-ltd-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-july-28-2025-urgn\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/urogen-pharma-ltd-class-action-the-gross-law-firm-reminds-urogen-pharma-ltd-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-july-28-2025-urgn\/","name":"UroGen Pharma Ltd. Class Action: The Gross Law Firm Reminds UroGen Pharma Ltd. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 28, 2025 - URGN - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/urogen-pharma-ltd-class-action-the-gross-law-firm-reminds-urogen-pharma-ltd-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-july-28-2025-urgn\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/urogen-pharma-ltd-class-action-the-gross-law-firm-reminds-urogen-pharma-ltd-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-july-28-2025-urgn\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2280333\/The_Gross_Law_Firm_Logo.jpg","datePublished":"2025-06-16T09:50:31+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/urogen-pharma-ltd-class-action-the-gross-law-firm-reminds-urogen-pharma-ltd-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-july-28-2025-urgn\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/urogen-pharma-ltd-class-action-the-gross-law-firm-reminds-urogen-pharma-ltd-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-july-28-2025-urgn\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/urogen-pharma-ltd-class-action-the-gross-law-firm-reminds-urogen-pharma-ltd-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-july-28-2025-urgn\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/2280333\/The_Gross_Law_Firm_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/2280333\/The_Gross_Law_Firm_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/urogen-pharma-ltd-class-action-the-gross-law-firm-reminds-urogen-pharma-ltd-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-july-28-2025-urgn\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"UroGen Pharma Ltd. Class Action: The Gross Law Firm Reminds UroGen Pharma Ltd. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 28, 2025 &#8211; URGN"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/860635","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=860635"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/860635\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=860635"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=860635"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=860635"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}